Module M1 suggested that Everolimus’s target MTOR was directly connected with multiple key AD pathology regulators, such as inhibitor of nuclear factor kappa B kinase subunit beta (IKBKB), FKBP prolyl isomerase 5 (FKBP5) (Fig 5D). This evidence concerns the gene FKBP5 and Alzheimer disease.